Linear connections with propagating spin-3 field in gravity

We show that Fronsdal's Lagrangian for a free massless spin-3 gauge field in Minkowski spacetime is contained in a general Yang--Mills-like Lagrangian of metric-affine gravity (MAG), the gauge theory of the general affine group in the presence of a metric. Due to the geometric character of MAG, this can best be seen by using Vasiliev's frame formalism for higher-spin gauge fields in which the spin-3 frame is identified with the tracefree nonmetricity one-form associated with the shear generators of GL(n,R). Furthermore, for specific gravitational gauge models in the framework of full nonlinear MAG, exact solutions are constructed, featuring propagating massless and massive spin-3 fields.Comment: References added. Minor corrections and clarifications. To be published in Phys. Rev.

New Renormalization Group Equations and the Naturalness Problem

Looking for an observable manifestation of the so-called unnaturalness of scalar fields we introduce a seemingly new set of differential equations for connected Green functions. These equations describe the momentum dependence of the Green functions and are close relatives to the previously known renormalization group equations. Applying the new equations to the theory of scalar field with $\phi^4$ interaction we identify a relation between the four-point Green function and the propagator which expresses the unnaturalness of the scalar field. Possible manifestations of the unnaturalness at low momenta are briefly discussed.Comment: 12 revtex pages; a coefficient has been corrected in eq. (34), four new references added; final version to appear in Phys. Rev.

Scalar Field Corrections to AdS_4 Gravity from Higher Spin Gauge Theory

We compute the complete contribution to the stress-energy tensor in the minimal bosonic higher spin theory in D=4 that is quadratic in the scalar field. We find arbitrarily high derivative terms, and that the total sign of the stress-energy tensor depends on the parity of the scalar field.Comment: 15 pages + appendix (30 pages

Higher spin AdS_3 supergravity and its dual CFT

Vasiliev's higher spin supergravity theory on three dimensional anti-de Sitter space is studied and, in particular, the partition function is computed at one loop level. The dual conformal field theory is proposed to be the N=(2,2) CP^N Kazama-Suzuki model in two dimensions. The proposal is based on symmetry considerations and comparison of the bulk partition function with the conformal field theory. Our findings suggest that the theory is strong-weak self-dual.Comment: 36 page

Bosons, fermions and anyons in the plane, and supersymmetry

Universal vector wave equations allowing for a unified description of anyons, and also of usual bosons and fermions in the plane are proposed. The existence of two essentially different types of anyons, based on unitary and also on non-unitary infinite-dimensional half-bounded representations of the (2+1)D Lorentz algebra is revealed. Those associated with non-unitary representations interpolate between bosons and fermions. The extended formulation of the theory includes the previously known Jackiw-Nair (JN) and Majorana-Dirac (MD) descriptions of anyons as particular cases, and allows us to compose bosons and fermions from entangled anyons. The theory admits a simple supersymmetric generalization, in which the JN and MD systems are unified in N=1 and N=2 supermultiplets. Two different non-relativistic limits of the theory are investigated. The usual one generalizes Levy-Leblond's spin 1/2 theory to arbitrary spin, as well as to anyons. The second, "Jackiw-Nair" limit (that corresponds to Inonu-Wigner contraction with both anyon spin and light velocity going to infinity), is generalized to boson/fermion fields and interpolating anyons. The resulting exotic Galilei symmetry is studied in both the non-supersymmetric and the supersymmetric cases.Comment: 54 pages. Typos corrected, refs updated. Published versio

Higher spin AdS_3 holography with extended supersymmetry

We propose a holographic duality between a higher spin AdS_3 gravity with so(p) extended supersymmetry and a large N limit of a 2-dimensional Grassmannian-like model with a specific critical level k=N and a non-diagonal modular invariant. As evidence, we show the match of one-loop partition functions. Moreover, we construct symmetry generators of the coset model for low spins which are dual to gauge fields in the supergravity. Further, we discuss a possible relation to superstring theory by noticing an N=3 supersymmetry of critical level model at finite k,N. In particular, we examine BPS states and marginal deformations. Inspired by the supergravity side, we also propose and test another large N CFT dual obtained as a Z_2 automorphism truncation of a similar coset model, but at a non-critical level.Comment: 44 pages, published versio

Feasibility studies for the measurement of time-like proton electromagnetic form factors from p¯ p→ μ+μ- at P ¯ ANDA at FAIR

This paper reports on Monte Carlo simulation results for future measurements of the moduli of time-like proton electromagnetic form factors, | GE| and | GM| , using the p¯ p→ μ+μ- reaction at P ¯ ANDA (FAIR). The electromagnetic form factors are fundamental quantities parameterizing the electric and magnetic structure of hadrons. This work estimates the statistical and total accuracy with which the form factors can be measured at P ¯ ANDA , using an analysis of simulated data within the PandaRoot software framework. The most crucial background channel is p¯ p→ π+π-, due to the very similar behavior of muons and pions in the detector. The suppression factors are evaluated for this and all other relevant background channels at different values of antiproton beam momentum. The signal/background separation is based on a multivariate analysis, using the Boosted Decision Trees method. An expected background subtraction is included in this study, based on realistic angular distributions of the background contribution. Systematic uncertainties are considered and the relative total uncertainties of the form factor measurements are presented

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.